1. Risk of hepatitis B virus reactivation in patients treated with ibrutinib
- Author
-
Nicolas C. Issa, Alisha Pandit, Francisco M. Marty, Matthew S. Davids, Kaiwen Chen, and Sarah P. Hammond
- Subjects
Oncology ,medicine.medical_specialty ,medicine.drug_class ,Immunology ,medicine.disease_cause ,Monoclonal antibody ,Biochemistry ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,hemic and lymphatic diseases ,Internal medicine ,medicine ,In patient ,030212 general & internal medicine ,Hepatitis B virus ,Hematopoietic cell ,business.industry ,Cell Biology ,Hematology ,Clinical trial ,Transplantation ,Increased risk ,chemistry ,030220 oncology & carcinogenesis ,Ibrutinib ,business - Abstract
TO THE EDITOR: Certain therapies for hematologic malignancies, including anti-CD20 monoclonal antibodies and allogeneic hematopoietic cell transplantation (allo-HCT), are associated with increased risk of hepatitis B virus (HBV) reactivation in patients previously infected with HBV.[1][1],[2][2]
- Published
- 2018